If you’ve been wanting to try psychedelic therapy legally, now’s your chance!
Johns Hopkins is recruiting participants for a number of psilocybin studies on:
Plus, Nova Mentis is recruiting both autisitc and neurotypical patients for an observational study that will lead to a psilocybin microdosing study.
If you want to contribute to psychedelic research from home, check out Johns Hopkins’ online surveys on psychedelics and breathwork for anxiety, depression, and PTSD.
A new Johns Hopkins study found that mystical psychedelic experiences are linked to changes in peoples’ beliefs about consciousness.
After a single psychedelic experience, people were much more likely to attribute consciousness to animals, insects, fungi, plants, and even inanimate objects. However, psychedelics had no effect on beliefs about free will or superstition.
What do you think — do mushrooms have consciousness?
Researchers from Yale, Johns Hopkins, and NYU are collaborating to develop a psychedelic therapy training program for psychiatrists. The project is funded by $1M in donations.
Johns Hopkins researchers followed up with patients one year after receiving psilocybin therapy. They found that 75% of patients sustained significant reductions in depression scores and 58% no longer qualified for a diagnosis.
However, about a third of patients also used traditional antidepressants and 42% received additional psychotherapy at some point during the year.
So although psilocybin therapy can have rapid results, multiple treatment options can help sustain the benefits.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please visit: https://nnw.fm/8YBVv
A small study by Johns Hopkins University published in “Journal of Psychopharmacology” compared smokers trying to quit using cognitive behavioral therapy (CBT) plus varying doses of psilocybin to abstinence rates typically observed in smokers using other medications or CBT alone. The results showed 67% of the participants remained nicotine free at a 12-month follow-up, a substantial increase over success rates for other methods (typically 10% to 35%). …
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is an integral part of this landmark NIH-funded research led by Johns Hopkins, a three-year, multisite smoking cessation study being conducted in collaboration with University of Alabama at Birmingham and New York University. Mydecine will be supplying its lead drug candidate, MYCO-001 (99% pure psilocybin), for use in the clinical trials. The supply agreement, in the words of Mydecine CEO Josh Bartch, “not only offers a significant opportunity to further advance our drug development through safer and more viable results but demonstrates Mydecine’s leadership position in the emerging psychedelic-assisted psychotherapy industry.”
About Mydecine Innovations Group
Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients.
For more information about the company, please visit www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.
NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).
For more information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website, applicable to all content provided by NNW wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Source: Mydecine Innovations Group Inc.
Released November 4, 2021
After half a century, the US federal government has started funding psychedelic research again!
A researcher at Johns Hopkins University received a U01 grant from the National Institute on Drug Abuse (NIDA) to fund a multi-site study on psilocybin for tobacco addiction, which will take place at Johns Hopkins, New York University, and the University of Alabama at Birmingham.
The researcher, Dr. Matthew W. Johnson, noted that this is the first time a psychedelic study has received funding since the War on Drugs was declared in the 70s, marking a “new era in legitimacy of psychedelic science”.
If cancer patients have the right to end their suffering through assisted suicide, shouldn’t they have the right to end their suffering through psilocybin therapy?
In a Johns Hopkins study, 92% of cancer patients saw significant reductions in depression and anxiety 5 weeks after a single high dose of psilocybin. After 6 months, 78% still had significant reductions in symptoms.
Many of the 51 participants described a sense of infinite love, peace, and oneness, and several were able to come to conquer their fear of death.
“It was so powerful and so profound that it just took my breath away… I feel like it changed my life”, said one participant, Anthony Head.
